Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.
Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses the multifaceted involvement of oncology pharmacists in various aspects of patient care.
Paul Forsberg, PharmD, BCOP, MHA, director of Pharmacy Services at Minnesota Oncology discusses how pharmacists can remain on top of shifts in the nature of biosimilar payer benefit design.
Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.
